<DOC>
	<DOCNO>NCT01024842</DOCNO>
	<brief_summary>In study , novel vaccine candidate , MVA.HIVconsv , test safety , tolerability immunogenicity HIV-1-seropositive subject receive effective antiretroviral therapy . MVA.HIVconsv test single vaccine modality , prelude test heterologous viral vector boost regimen include replication-defective simian adenovirus express immunogen .</brief_summary>
	<brief_title>Safety Immunogenicity MVA.HIVconsv HIV-1 Seropositive Adults HAART</brief_title>
	<detailed_description />
	<criteria>Male female , age 1860 year Confirmed HIV1 seropositive Willing able give write informed consent participation study Treated continuously combination 3 antiretroviral agent precede 12 month Willing able adhere effective ART regimen duration study ( switch current regimen allow reason tolerability toxicity ) CD4 cell count &gt; 350 cells/μl screen precede clinic visit Plasma viral load &lt; 50 copy / ml screen precede clinic visit No new AIDSdefining diagnosis progression HIVrelated disease precede 6/12 month Haematological biochemical laboratory parameter follow : Haemoglobin &gt; 10g/dl Platelets &gt; 100,000/μl ALT ≤ 2.5 x ULN Creatinine ≤ 1.3 x ULN Serology : negative hepatitis B surface antigen OR HbsAg positive HBV DNA &lt; 1000 copies/ml ; negative hepatitis C antibodies OR confirm clearance HCV infection ( spontaneous follow treatment ) ; negative syphilis serology document adequate treatment syphilis positive EIA IgG TPHA Available follow duration study ( screen + 38 week ) willing comply protocol requirement Women childbearing age must pregnant , plan pregnancy breastfeeding . Sexually active woman must willing use approve method contraception screen 4 month third immunisation . Sexually active men heterosexual relationship must willing use approve method contraception partner screen 4 month third immunisation . Confirmed HIV2 seropositive Positive pregnancy test Participation another clinical trial within 12 week study entry History autoimmune disease HIVrelated autoimmune disease resolve ART History clinical manifestation physical psychiatric disorder could impair subject 's ability complete study History anaphylaxis severe adverse reaction vaccine History alcohol drug dependency could , opinion investigator , impair subject 's ability complete study Previous immunisation recombinant MVA vaccine Immunisation experimental immunogen within 6 month study entry Receipt blood product immunoglobulins within 6 month study entry Treatment cancer lymphoproliferative disease within 1 year study entry Receipt vaccine Hepatitis B vaccine within 2 week study entry plan receipt within 2 week vaccination Any prior therapy , opinion investigator , would make individual unsuitable study influence result study Current recent use ( within last 3 month ) interferon systemic corticosteroid immunosuppressive agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>